Cutaneous Leishmaniasis Clinical Trial
Official title:
Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco
Verified date | August 2017 |
Source | National School of Public Health, Morocco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this study is to estimate the accuracy of CL Detect Rapid Testâ„¢ compared to a composite reference standard test (Direct examination of skin smears + PCR test) in patients with clinically suspected Cutaneous Leishmaniasis disease in Morocco.
Status | Completed |
Enrollment | 219 |
Est. completion date | August 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 5 Years and older |
Eligibility |
Inclusion Criteria: - Participants with suspected Cutaneous Leishmaniasis wound(s) in apparently healthy state - Who is able to learn the Information sheet and sign the Informed consent form by them selves or by their parents with the presence or not of a witness (for illiterate people) - Who satisfy the following criteria : - with an ulcerative lesion in any accessible part of the body to perform the dental broach and the scraping. - Just one ulcerative lesion by patient could be selected (The newest and the less infected) - Lesion should be less than 04 months of age Exclusion Criteria: - Patients with only nodular, papular, macular or nodulo-papular suspected CL forms - Patients with ulcerative lesions with a suspected bacteria origin which could disappear after a short course of antibiotic treatment. - Patients who already received during the last two months, prior to signing the consent, a physical treatment (e.g. cryotherapy, thermotherapy, Laser) or a traditional treatment (e.g. burn, acide, traditional scraping) - Patients presenting other disease with the need to take anti-parasite treatments - Patient with a acute or chronic disease needing hospitalization - Patient who already received antimoniate treatment incomplete or complete duration and dose against CL - Any situation that could engage the security of the patient or of the health professional (e.g. People with a psychiatric trouble or a mental handicap ) - For children less than 12 years old, the decision of participation is mainly based on the condition that their parents are able to learn and understand the information sheet and sign the informed consent form |
Country | Name | City | State |
---|---|---|---|
Morocco | Primary Health Center | Boumalne | Tinghir |
Morocco | Primary Health center | Erfoud | Errachidia |
Morocco | Primary Health Center | Kelaat Mgouna | Tinghir |
Morocco | Primary Health Center | Sefrou | |
Morocco | Primary Health Center | Sekoura | Ouarzazates |
Morocco | Primary Health Center | Sidi Kacem | |
Morocco | Primary Health Center | Tarmight | Ouarzazates |
Morocco | Primary Health Center | Tazouta | Sefrou |
Morocco | Health primary center | Tinejdad | Errachidia |
Lead Sponsor | Collaborator |
---|---|
National School of Public Health, Morocco | Institute of Tropical Medicine, Belgium |
Morocco,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive result for this test | 50 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01988909 -
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Enrolling by invitation |
NCT00840359 -
Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Enrolling by invitation |
NCT00737386 -
Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank
|
N/A | |
Completed |
NCT00233545 -
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
|
Phase 2 | |
Completed |
NCT01462500 -
Pharmacokinetics of Miltefosine in Children and Adults
|
Phase 4 | |
Completed |
NCT01011309 -
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT01301924 -
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02281669 -
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
|
N/A | |
Completed |
NCT01464242 -
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Completed |
NCT01790659 -
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
|
Phase 3 | |
Completed |
NCT01050907 -
Miltefosine to Treat Mucocutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT04340128 -
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
|
Phase 3 | |
Completed |
NCT00351520 -
Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica
|
Phase 3 | |
Terminated |
NCT00317629 -
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
|
Phase 3 | |
Completed |
NCT01381055 -
Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis
|
Phase 2/Phase 3 | |
Completed |
NCT01050777 -
Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
|
Phase 0 | |
Completed |
NCT01380314 -
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
|
Phase 2 | |
Terminated |
NCT01380301 -
Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
|
Phase 2 | |
Completed |
NCT00703924 -
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
|
Phase 2 | |
Completed |
NCT00344084 -
Surveillance for Leishmaniasis Skin Lesions in Mali
|